fda warning letter hims compounded semaglutide september 2025 & Hers' Super Bowl ad turns up the heat on GLP-1 battle Hims & Hers compounder received

Historically, Medicare Part D has generally not covered medications used only for weight loss

The key is consistency , not complexity

Proportional hazards tests and diagnostics based on weighted residuals

Depress the plunger slowly, allowing the water to trickle down the glass wall and pool at the bottom

Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold

For instance: Ozempic (semaglutide) is approved to lower the risk of major cardiovascular events like heart attacks or strokes in adults with type 2 diabetes